<DOC>
	<DOCNO>NCT00004014</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal doxorubicin treat patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Liposomal Doxorubicin Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate objective response rate patient hormone refractory prostate cancer treat doxorubicin HCl liposome . II . Determine toxic effect ( include cumulative cardiotoxicity ) regimen patient . III . Assess effect regimen pain quality life patient . OUTLINE : Patients receive doxorubicin HCl liposome IV 45 minute every 3 week . Treatment continue absence disease progression unacceptable toxicity . Quality life assess baseline every 9 week thereafter . Patients follow every 3 month . PROJECTED ACCRUAL : Approximately 50 evaluable patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hormone refractory prostate cancer Castrate serum testosterone level less 30 mg/dL occur least 4 week since prior flutamide least 6 week since prior bicalutamide Measurable evaluable progressive disease Rising PSA involve two determination ( one least 20 ng/mL PSA sole criterion ) least two week apart OR Increasing measurable evaluable disease OR New metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL No hepatic insufficiency Renal : Creatinine great 2.0 mg/dL No renal failure Cardiovascular : Cardiac ejection fraction least 50 % radionuclide ventriculogram No myocardial infarction within past year No active angina No congestive heart failure No arrhythmia require medication Other : No active peptic ulcer No uncontrolled infection serious medical condition would prevent compliance chemotherapy No uncontrolled diabetes No spinal cord compression carcinomatous meningitis PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid therapy Concurrent gonadotropinreleasing hormone analogue allow Radiotherapy : At least 2 month since prior radiotherapy ( measurable lesion ) Concurrent palliative radiotherapy allow Surgery : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>recurrent prostate cancer</keyword>
</DOC>